Founded in 2022 in Gironde by veterinarian Romain Delcombel, BioAz is a young animal-health biotech focused on replacing the controversial practice of piglet castration with an immunotherapy approach. Its lead solution aims to neutralize boar taint through a vaccine-like treatment, eliminating the need for surgical intervention and improving animal welfare. The company positions itself at the crossroads of animal health and sustainable livestock production, targeting pork producers and integrators that face increasing regulatory and consumer pressure. BioAz plans to use newly raised capital to accelerate R&D, deepen scientific collaborations, and scale industrial deployment of its first products. While still in early development, the startup has garnered interest from industry-specific investors, underscoring market demand for welfare-friendly animal health innovations. To date, BioAz has secured €900 000 in external funding; no revenue or user metrics have been disclosed.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2026